Health Economic Evaluation of Rivaroxaban in Elective Cardioversion of Atrial Fibrillation

European Journal of Health Economics - Germany
doi 10.1007/s10198-017-0942-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Takotsubo Cardiomyopathy as a Sequela of Elective Direct-Current Cardioversion for Atrial Fibrillation

Texas Heart Institute Journal
MedicineCardiovascular MedicineCardiology
2014English

Pharmacological Cardioversion of Long-Lasting Atrial Fibrillation

Circulation Journal
MedicineCardiovascular MedicineCardiology
2007English

Paroxysmal Atrial Fibrillation: Choice of Cardioversion Therapy

Rational Pharmacotherapy in Cardiology
Cardiovascular MedicinePharmacologyCardiology
2007English

Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation

Yearbook of Cardiology
2012English

Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48

Clinical Cardiology
MedicineCardiovascular MedicineCardiology
2016English

Correct Technique Is Important in Cardioversion of Atrial Fibrillation

BMJ
1996English

External Cardioversion in Patients With Persistent Atrial Fibrillation

Japanese Heart Journal
2003English

Ogilvie’s Syndrome Following Cardioversion for Atrial Fibrillation

Case Reports in Medicine
Medicine
2014English

Vertebral Fracture Resulting From Cardioversion for Atrial Fibrillation

Journal of Interventional Cardiac Electrophysiology
MedicineCardiovascular MedicinePhysiologyCardiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy